{"transactions":[{"id":4082500,"issuer":{"id":8383,"kind":"organization","name":"Capstone Holding Corp."},"owners":[{"id":24804,"kind":"person","name":"Lipman Matthew E.","position":1,"cik":"0001687758","reported_name":"Lipman Matthew E.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":169924,"kind":"person","name":"BP Peptides, LLC","position":2,"cik":"0001711689","reported_name":"BP Peptides, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2018-02-01T23:00:35.000Z","date":"2018-01-30","kind":"other","acquired":true,"shares":1,"ownership":{"direct":false,"nature":"By: BP Peptides, LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by BP Peptides, LLC (\"BP Peptides\") and Matthew E. Lipman (collectively, the \"Reporting Persons\"). Mr. Lipman is a director of the Issuer. BP Peptides may be deemed to be a director by deputization by virtue of the fact that Mr. Lipman, the Manager and President of BP Peptides, is a director of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Warrant was issued by the Issuer to BP Peptides in consideration of BP Peptides' agreement to defer all accrued but unpaid interest due under its loan to the Issuer until October 15, 2020 (the \"Maturity Date\").  The Warrant vests quarterly in accordance with Schedule 1 thereto and will be fully vested on the Maturity Date; provided, however, that in the event of a Deferred Interest Repayment (as defined in the Warrant), then all vesting shall immediately terminate and lapse as to any Warrant shares that have not yet vested and none of such Warrant shares shall become vested.  In no event may the Warrant be exercised if and to the extent that such exercise would be inconsistent with or constitute a violation of the Issuer's Tax Benefit Preservation Plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Warrant was issued by the Issuer to BP Peptides in consideration of BP Peptides' agreement to defer all accrued but unpaid interest due under its loan to the Issuer until October 15, 2020 (the \"Maturity Date\").  The Warrant vests quarterly in accordance with Schedule 1 thereto and will be fully vested on the Maturity Date; provided, however, that in the event of a Deferred Interest Repayment (as defined in the Warrant), then all vesting shall immediately terminate and lapse as to any Warrant shares that have not yet vested and none of such Warrant shares shall become vested.  In no event may the Warrant be exercised if and to the extent that such exercise would be inconsistent with or constitute a violation of the Issuer's Tax Benefit Preservation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrant was issued by the Issuer to BP Peptides in consideration of BP Peptides' agreement to defer all accrued but unpaid interest due under its loan to the Issuer until October 15, 2020 (the \"Maturity Date\").  The Warrant vests quarterly in accordance with Schedule 1 thereto and will be fully vested on the Maturity Date; provided, however, that in the event of a Deferred Interest Repayment (as defined in the Warrant), then all vesting shall immediately terminate and lapse as to any Warrant shares that have not yet vested and none of such Warrant shares shall become vested.  In no event may the Warrant be exercised if and to the extent that such exercise would be inconsistent with or constitute a violation of the Issuer's Tax Benefit Preservation Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities owned directly by BP Peptides. As the Manager and President of BP Peptides, Mr. Lipman may be deemed to beneficially own the securities owned directly by BP Peptides. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."}],"balance_after":1,"derivative":{"exercise_price":0.075,"expiration_date":"2025-10-15","underlying":"Common Stock, $0.0005 par value","underlying_shares":6321930},"source":{"system":"sec-edgar","filing":"0000921895-18-000366","document":"form410959006_02012018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887151/000092189518000366/form410959006_02012018.xml","form_type":"4"}}]}